A novel Deep TMS system was developed for treating clinically depressed patients.
The safety of the system was proved in a clinical study with healthy volunteers, performed at the Shalvata Mental Health Center. The study also demonstrated a significant improvement in several cognitive tasks.
The FDA* has granted Brainsway a wide indication for the treatment of Depression patients who did not benefit from any number of previous medication treatments. The indication was issued following a multicenter clinical trial for the assessment of the efficacy and safety of Deep TMS in subjects suffering from major depression disorder (MDD). Brainsway's treatment was proved to be safe, as the treatment was well tolerated by the majority of the study subjects with no severe adverse effects.